Voorzichtig met erytropoëtine bij patiënten met kanker

J. van der Lelie

Voorzichtig met erytropoëtine bij patiënten met kanker

J. van der Lelie^*

^*Corresponding author for this work

Amsterdam UMC - University of Amsterdam

Research output: Contribution to journal › Comment/Letter to the editor › Professional

Abstract

Erythropoietin has been shown to shorten survival in cancer patients under certain circumstances. Possible mechanisms are an increase in thrombotic events, tumour progression, and induction of angiogenesis. The FDA advises its use in oncology only as a replacement for blood transfusions in patients receiving chemotherapy. In these patients, a rise in haemoglobin above 7.4 mmol/l should be avoided.

Original language	Dutch
Pages (from-to)	920-922
Journal	Nederlands tijdschrift voor geneeskunde
Volume	152
Issue number	16
Publication status	Published - 19 Apr 2008
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{23adff8b9f0047b2952eb9380d23e3d7,

title = "Voorzichtig met erytropo{\"e}tine bij pati{\"e}nten met kanker",

abstract = "Erythropoietin has been shown to shorten survival in cancer patients under certain circumstances. Possible mechanisms are an increase in thrombotic events, tumour progression, and induction of angiogenesis. The FDA advises its use in oncology only as a replacement for blood transfusions in patients receiving chemotherapy. In these patients, a rise in haemoglobin above 7.4 mmol/l should be avoided.",

author = "\{van der Lelie\}, J.",

year = "2008",

month = apr,

day = "19",

language = "Dutch",

volume = "152",

pages = "920--922",

journal = "Nederlands tijdschrift voor geneeskunde",

issn = "0028-2162",

publisher = "Bohn Stafleu Van Loghum",

number = "16",

}

TY - JOUR

T1 - Voorzichtig met erytropoëtine bij patiënten met kanker

AU - van der Lelie, J.

PY - 2008/4/19

Y1 - 2008/4/19

N2 - Erythropoietin has been shown to shorten survival in cancer patients under certain circumstances. Possible mechanisms are an increase in thrombotic events, tumour progression, and induction of angiogenesis. The FDA advises its use in oncology only as a replacement for blood transfusions in patients receiving chemotherapy. In these patients, a rise in haemoglobin above 7.4 mmol/l should be avoided.

AB - Erythropoietin has been shown to shorten survival in cancer patients under certain circumstances. Possible mechanisms are an increase in thrombotic events, tumour progression, and induction of angiogenesis. The FDA advises its use in oncology only as a replacement for blood transfusions in patients receiving chemotherapy. In these patients, a rise in haemoglobin above 7.4 mmol/l should be avoided.

UR - https://www.scopus.com/pages/publications/44949145219

UR - https://www.ncbi.nlm.nih.gov/pubmed/18561786

M3 - Comment/Letter to the editor

C2 - 18561786

SN - 0028-2162

VL - 152

SP - 920

EP - 922

JO - Nederlands tijdschrift voor geneeskunde

JF - Nederlands tijdschrift voor geneeskunde

IS - 16

ER -

Voorzichtig met erytropoëtine bij patiënten met kanker

Abstract

UN SDGs

Other files and links

Cite this